Bavarian Nordic was late to the vaccine party – but don't count them out just yet According to two analysts and an expert virologist, developing a diverse portfolio of Covid-19 vaccines which use different technologies makes sense. Photo: Dado Ruvic/Reuters/Ritzau Scanpix by christian bundgaard and ulrich quistgaard, translated by catherine brett Published: 27.06.22 at 12:51 Of course there is a market for Bavarian Nordic’s Covid-19 vaccine candidate, ABNCoV2. Already a subscriber? Log in. Read the whole article Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial. Access all locked articles Receive our daily newsletters Access our app First name: Last name: E-mail address: Password: I accept the terms and conditions An error has occured. Please try again later. Create trial Get full access for you and your coworkers. Start a free company trial today More from MedWatch Sonova completes Hysound Group acquisition, strengthens presence in China The hearing aid giant now owns over 200 hearing clinics in China. Extra data boosts Lundbeck's agitation case Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients. FDA confirms rejection of Y-mabs' cancer drug The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October. Top news from MedWatch this week Miss anything? Acquisitions to help Coloplast attain growth goal Coloplast aims to grow by 10%, and chairman of the board Lars Rasmussen thinks this will be realized through multiple acquisitions. Print Print Increase text size Increase text size Decrease text size Decrease text size Further reading Analyst spies alternative buyers in the wings as Cochlear's potential Oticon acquisition raises eyebrows FDA approves Ferring microbiotica-based treatment Novo reaches share milestone, analyst credits Wegovy Novo Nordisk to test best-selling substance in stroke indication Acquisitions to help Coloplast attain growth goal Related articles Moderna on booster race: May the best data win Biontech wants to save the world by developing drugs without clear commercial potential Novavax vaccine recommended for approval for EU teenagers Epidemiologist calls Pfizer's corona pill a "game changer"